First hormone replacement therapy for parathyroid disorder

27 Feb 2017


The European Medicines Agency has recommended granting a conditional marketing authorisation in the EU for an orphan medicine proposed as a treatment for chronic hypoparathyroidism, in patients poorly controlled using standard treatments.

European Medicines Agency


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story